People on the move.
Fremont, CA (Aug. 21)— PDL BioPharma's chief executive Mark McDade will resign by the end of 2007. An internal investigation found no credible evidence of improper personal conduct or breach of fiduciary duty.
Stockholm, Sweden (Aug. 17)— Orexo appointed three senior executives: Mats Eriksson, PhD, to vice-president of research and clinical development and medical director; Christina Ståhl, MSc. Pharm, to vice-president of regulatory affairs; and Anne Marie Ciupitu, MSc, PhD, to director of quality assurance and quality controlWoburn, MA (Aug. 15)— BioVex, a biotechnology company developing clinical-stage treatments, appointed Dr. Thaddeus Pullano as vice-president of quality assurance.
Palo Alto, CA (Aug. 14)— Affymax named Robert Venteicher as the company's vice-president of technical operations. In this position, Venteicher will oversee manufacturing and process development, quality, and facility operations for Affymax.
Shanghai, China (Aug. 13)— WuXi PharmaTech, a provider of pharmaceutical research and development outsourcing services, appointed Edward Hu executive vice-president of operations. Hu will report directly to Ge Li, chairman and chief executive officer of the company.
Westbrook, ME (Aug. 13)— Artel, a provider of liquid-handling quality assurance, appointed Bjoern Carle, PhD, laboratory applications scientist.
Markham, ON, Canada (Aug. 13)—Joel Z. Melnick, MD, joined Cytochroma as vice-president of clinical and regulatory affairs. Melnick will be responsible for managing the clinical development of Cytochroma's new Vitamin D therapies and for obtaining marketing approvals from the US Food and Drug Administration and Canada's Therapeutic Products Directorate.
New York (Aug. 10)—The pharmaceutical company ImClone Systems appointed John H. Johnson as its chief executive officer, effective August 27, 2007.
Vancouver, BC, Canada (Aug. 10)— ProtoKinetix appointed Ross L. Senior its president and CEO.
Toronto, ON, Canada (Aug. 9)— PharmEng International, a consulting and contract manufacturing company, appointed David G. Leonard the Keata Pharma president for the Sydney, Nova Scotia, Canada, and Perth, Ontario, Canada, manufacturing sites. Keata Pharma is a wholly owned subsidiary of PharmEng with manufacturing facilities in Perth and new facilities in Sydney scheduled to open in the fourth quarter of this year.
Bridgewater, NJ (Aug. 9)— Sapphire Therapeutics, a private biopharmaceutical company, announced a promotion and a new addition to the firm. Eleanor de Groot was promoted to vice-president of technical operations, with increased responsibilities for all drug development and manufacturing activities at the company. Brenda Marczi will join Sapphire as vice-president of regulatory affairs.